Allergan Announces FDA Approval of ACULAR LS Ophthalmic Solution; The New Formulation of the #1 Prescribed Ophthalmic NSAID in the United States.

Publication: Business Wire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2003 Business Wire

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--June 2, 2003

Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved ACULAR LS(TM) (ketorolac tromethamine ophthalmic solution) 0.4% for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

ACULAR LS(TM) is a new, optimized formulation of ketorolac tromethamine and joins this family of products used for a range of other conditions including post-surgical...

Read the full article for free courtesy of your local library.